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group (P = 0.0053), suggesting a directly nephroprotective role of
NO. However, no assesment of right heart function and no detailed
hemodynamic measurements were presented.
To determine both the cardiac and renal protective effects
of NO during cardiac surgery and the potential cardio–renal
interactions that might occur, we are now conducting a randomized
trial in 250 cardiac surgery patients at the Massachusetts General
Hospital (Boston, MA) with intraoperative echocardiography
and pulmonary artery catheterization. We will measure renal
biomarkers, assess pre- and postoperative redox states, and
evaluate pre- and postoperative levels of plasma NO metabolomics.
The primary endpoint of this ongoing study in Boston is to
determine whether NO is effective in the prevention of AKI as
defined by Kidney Disease Improving Global Outcomes criteria
(ClinicalTrials.gov Identifier: NCT02836899). However, in
contrast to our first trial in China in patients primarily with
rheumatic heart disease, Americans undergoing heart surgery
are generally older and are affected by endothelial dysfunction.
Endothelial dysfunction is a condition characterized by impaired
endothelial NO synthase. In these patients, the diseased
endothelium is unable to provide appropriate vasodilation
during and after ischemic events, and is unable to replenish
plasma NO after consumption of NO from intravascular
hemolysis (5). At present (January 2019), we are halfway through
enrollment (n = 125). We believe that the results of this ongoing
trial will be able to address the hypothesis of Dr. Coutrot
and colleagues. n
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Enhancing the Expression of CFTR Using
Antisense Molecules against MicroRNA miR-145-5p
To the Editor:
We read with great interest the article titled “MicroRNA-145
Antagonism Reverses TGF-b Inhibition of F508del CFTR
Correction in Airway Epithelia” by Lutful Kabir and colleagues (1).
In this paper, the authors demonstrate that miR-145 mediates
TGF-b (transforming growth factor-b) inhibition of synthesis and
function of CFTR (cystic fibrosis transmembrane conductance
regulator) in cystic fibrosis (CF) airway epithelia. Interestingly, they
found that antagonists of miR-145 were able to interrupt TGF-b
signaling and restore F508del CFTR modulation. Therefore, they
suggested that miR-145 targeting may provide a novel therapeutic
opportunity to enhance the benefit of F508del CFTR correction in
CF epithelia. In agreement with this, we have elsewhere published
data supporting the use of miR-145 targeting in CF, based on an
antisense peptide nucleic acid (PNA) to target miR-145-5p (PNA-
a145) and enhance expression of the CFTR gene, which we
analyzed at mRNA (qRT-PCR) and protein (Western blotting)
levels (2). In support of the conclusion by Lutful Kabir and
colleagues, our data suggest the use of suitably delivered antisense
molecules targeting miR-145-5p to enhance the expression of
CFTR (2).
With respect to a possible microRNA (miRNA)-based
therapeutic option, one limitation is of course the presence
of more than 300 CFTR gene disease-causing mutations
(www.genet.sickkids.on.ca/cftr/) (3). Besides the CFTR mutation
leading to the deletion of the phenylalanine in position 508 (F508del
CFTR), accounting for 50–90% CF chromosomes, most CF-
causing mutations are missense (42%), nonsense (10%), frameshift
(15%), splicing (13%), in-frame deletion/insertion (2%), and
promoter (0.5%) mutations, which are now operationally
categorized in six classes of molecular defects of the CFTR
protein (3).
In consideration of these different molecular defects, it is
expected that targeting miR-145 could be useful for type IV (less
function), V (less protein), and VI (less stable protein) CFTR defects.
For CFTR defects such as type I (no protein), II (no traffic), and III
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(no function), miR-145 targeting may be considered only in
combination with other therapeutic protocols. In conclusion, in
agreement with Lutful Kabir and colleagues, and considering
the increasing relevance of RNA-targeted therapies (4), combined
therapy with innovative oligonucleotides or peptide–nucleotide
chimeras targeting miR-145 might be considered together
with CFTR correctors such as lumacaftor, tezacaftor (1, 3), and
4,6,49-trimethylangelicin (3, 5).
In addition, using next-generation sequencing of the miRNome,
we recently observed that the majority of miRNAs (81.6%) are not
modulated in Calu-3 cells treated with the anti-miR145 PNA
(unpublished results). On the other hand, we observed that inhibition
of miR-145-5p with PNA might also be accompanied by coinhibition
of other miRNAs (12.5%), among which of great interest in our
opinion is miR-155-3p. Our next-generation sequencing data,
validated by qRT-PCR and droplet digital RT-PCR, demonstrated
that treatment of Calu-3 cells with PNA-a145 resulted in inhibition of
miR-145-5p and miR-155-3p by 34–43% and 42–44%, respectively.
This is of interest because miR-155-3p upregulation has been
reported to be responsible for hyperactivating IL-8, thereby
amplifying the deleterious effects of excessive inflammation on CF
lung tissues (6). Therefore, in addition to upregulation of CFTR
(1, 2), PNA-mediated targeting of miR-145-5p might be expected
to lead to downregulation of IL-8, possibly combining two
activities of great interest in CF therapy, i.e., the rescue and
potentiation of mutant CFTR protein and the control of lung
inflammation. n
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Reply to Finotti et al.
To the Editor:
Fabbri and colleagues’ investigations (1) complement well the work
of our group (2) and others (3–5) to emphasize the importance of
the TGF-b (transforming growth factor-b)/miR-145 (microRNA
145) axis in regulating CFTR (cystic fibrosis transmembrane
conductance regulator) expression and function in airway epithelia.
In brief, miR-145 mediates TGF-b suppression of CFTR through
miR-145 binding to the 39-untranslated region (39-UTR) of CFTR
mRNA. TGF-b/miR-145 stimulation nullifies the benefit of
currently available CFTR modulators, and miR-145 antagonism
augments F508del correction. The authors outline well the
therapeutic potential of miR-145 antagonism for each CFTR
mutational category (e.g., class I–VI defects).
In their letter to the editor, Finotti and colleagues elucidate two
important considerations in the development of oligotherapeutics:
target specificity and preclinical model selection. With regard to
antagonist selection, the question arises as to whether to block the
microRNA (miRNA) itself (full antagonism) or the binding site on the
transcript of interest (target site blockade). Pursuing the latter
approach, we use an antisense oligonucleotide to block miR-145
binding to the CFTR 39-UTR sequence and limit off-target disruption
of TGF-b signaling. Finotti and colleagues describe the possible
benefit of full miR-145 antagonism to suppress additional
consequences of increased TGF-b stimulation. Their letter highlights
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